Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502786 · ClinicalTrials.gov registry record · Phase 2
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
A Phase 2 study of Recurrent Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 3
- Study locations
NCT02502786: Active Phase 2 study of Recurrent Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02502786 is a Phase 2 study of Recurrent Osteosarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants, below the 63-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (27% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502786, a Phase 2 study of Recurrent Osteosarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
Primary Outcome
EFS is defined as the time from surgery to relapse or death from any cause, recurrence of tumor or second malignancy.
Conditions Studied
Interventions
- DRUG GM-CSF
- BIOLOGICAL humanized anti-GD2 antibody
Study Locations (3)
California
- Children's Hospital of Los Angeles (Data Collection Only) - Los Angeles
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD ANDERSON CANCER CENTER (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-07 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT02502786 still lists
NCT02502786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 63-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which GM-CSF is the first listed.
NCT02502786 reports a single indexed study location in California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02502786 about?
NCT02502786 is a clinical study titled "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma". The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
What is the current status of trial NCT02502786?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2015-07. Estimated completion is 2026-07.
What conditions does trial NCT02502786 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma.
What interventions are being tested in trial NCT02502786?
The interventions under investigation include: GM-CSF (DRUG), humanized anti-GD2 antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT02502786?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502786 being conducted?
This trial has 3 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02502786's enrollment target sits among peer trials
46 6th of 13 higher than 8 of 13 other Recurrent Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
-
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia